EHC Stock Analysis — Encompass Health
Sector: Healthcare
AI Verdict
EHC trades at 17.4x next year's earnings with 6.8% expected EPS growth—cheap compared to healthcare peers, but the moat from regulatory barriers and hospital ties must keep delivering to justify even this moderate multiple.
Competitive Moat
Encompass Health operates a nationwide network of inpatient rehabilitation hospitals, benefiting from high regulatory barriers and referral relationships with acute care providers. Its scale and integration with hospital systems create switching costs for patients and partners.
Summary
EHC stands out for its consistent double-digit revenue growth in a highly regulated healthcare niche.
Where It Stands
EHC delivered 10.5% revenue growth and trades at 17.4x forward earnings, a discount to the healthcare sector median of 22x.
Key Metrics
- Trailing P/E: 18.6x
- Forward P/E: 17.4x
- PEG Ratio: 2.75
- Earnings Growth: +0.1%
- Revenue Growth: +0.1%
- Dividend Yield: 0.01%
- 52-Week High: $127.99
- 52-Week Low: $92.77
Analyst Consensus
15 Buy · 1 Hold · 0 Sell (16 analysts)
Bull Case
Forward EPS is expected to grow 6.8% while the stock trades below sector P/E norms at 17.4x, suggesting investors are paying less for stable earnings expansion.
Bear Case
A trailing PEG of 2.75 signals investors are paying a premium the growth rate doesn't fully support, so if the P/E falls to the sector median of 22x, upside is capped unless growth accelerates.
Catalyst to Watch
Watch for regulatory changes or hospital partnership announcements that could materially shift referral volumes.